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Abstract
Hepatocellular carcinoma (HCC) commonly occurs in 
hepatitis B endemic areas, especially in Asian countries. 
HCC is highly refractory to cytotoxic chemotherapy. 
This resistance is partly related to its tumor biology, 
pharmacokinetic properties, and both intrinsic and 
acquired drug resistance. There is no convincing 
evidence thus far that systemic chemotherapy 
improves overall survival in advanced HCC patients. 
Other systemic approaches, such as hormonal therapy 
and immunotherapy, have also disappointing results. 
Recently, encouraging results have been shown in 
using sorafenib in the treatment of advanced HCC 
patients. In this review, we concisely summarize the 
evolution of developments in the systemic therapy of 
advanced HCC.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth ranking 
cancer in the world, with more than 80% of  cases 
occurring in Asia[1]. The most common causes of  HCC 
are hepatitis B and C viral infections. Chronic hepatitis 
B viral infection is prevalent in Asian countries and 
accounts for most cases of  HCC. In contrast, chronic 
hepatitis C viral infection is more common in Western 
countries. In recent years, there is an increasing incidence 
of  HCC in Western countries, primarily due to increase 
in prevalence of  hepatitis C viral infection.
Current effective treatments for HCC include 
liver resection, transplantation, various local ablative 
and trans-arterial therapies. Surgical resection and 
liver transplantation are the main curative treatments. 
Unfortunately, only around 20% patients, mostly 
diagnosed by regular screening, may benefit from these 
surgical therapies. Most other patients either present 
late with advanced tumor or have severe underlying 
cirrhosis, precluding any surgical or even loco-regional 
therapies. Previously, these patients can only be palliated 
by chemotherapy or best supportive treatment alone.
CHEMOTHERAPY TREATMENT OF HCC
HCC is a relatively chemo-resistant tumor and is highly 
refractory to cytotoxic chemotherapy. This resistance 
is partly related to its tumor biology, pharmacokinetic 
properties, and both intrinsic and acquired drug resistance.
In terms of  HCC tumor biology, the liver is a 
defensive organ that responds to the damages in a 
unique manner. Non-hepatic epithelial cells progress 
through the cell cycle until they either die or arrest/
repair; whereas growth-arrested (i.e. G0) hepatocytes 
proliferate in response to damage[2,3]. In fact, HCC cells 
show a higher apoptotic capacity in earlier stages of  
carcinogenesis. Nonetheless, in advanced stages, they 
gradually develop the resistance to apoptosis. This anti-
apoptotic phenotype is associated with the development 
and progression of  HCC[4]. More importantly, it also 
partly explains why HCC cells are resistant to cytotoxic 
chemotherapy. Moreover, p53 mutation is the most 
commonly encountered alternations in HCC. Both 
hepatitis viruses and chemicals are implicated in 
the etiology of  p53 mutations during the molecular 
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pathogenes is  of  HCC [5].  As chemotherapeut ic 
agents require p53 to induce apoptosis, tumors with 
a disruption in p53 pathway are thus resistant to 
chemotherapy. Furthermore, DNA topoisomerase Ⅱ 
alpha is over-expressed and up-regulated in HCC cell 
lines. Since doxorubicin targets DNA topoisomerase Ⅱ, 
over-expression of  the protein in HCC may account 
for HCC resistance to doxorubicin-based therapy[6]. 
Regarding its pharmacokinetic properties, the liver plays 
a pivotal role in the metabolism of  both endogenous 
and exogenous substances inside the body via the 
CYP450 enzyme system[7]. In cirrhotic patients, the 
total liver mass is reduced, and distortion of  the liver 
architecture leads to significant intra-hepatic shunting 
and reduced extraction of  protein-bound substances. 
Moreover, cirrhosis also affects the absorption, plasma 
protein binding, distribution and renal excretion of  
drugs. Therefore, cirrhosis has a significant impact on 
the pharmacokinetics of  systemic therapy for HCC. 
Lastly, HCC cells have intrinsic drug resistance mediated 
by an enhanced cellular drug efflux mechanism, which is 
usually enacted through the drug transporter family of  
the ATP-binding cassette proteins that include MDR1, 
p-glycoprotein and the multidrug resistance protein[8,9]. 
Moreover, co-expression of  p53 and p-glycoprotein also 
contribute to HCC drug resistance[9].
There is no convincing evidence, thus far, that 
systemic chemotherapy improves overall survival in 
advanced HCC patients[10]. Table 1 summarizes the 
results of  pivotal chemotherapy studies of  HCC. 
Single-agent doxorubicin has been shown to produce a 
response rate of  about 10%-15%, but with no proven 
survival benefit[11]. It has been widely used and regarded 
as the standard systemic treatment for advanced HCC 
until recently. Significant grade 3 or 4 toxicities, especially 
neutropenia, are encountered in patients treated with 
doxorubicin[12]. Other chemotherapeutic agents, such 
as epirubicin, cisplatin, 5-fluorouracil, etoposide, 
and their combinations, have been studied with low 
response rates and no survival benefit[13]. Similarly, the 
newer generation of  chemotherapeutic agents, such 
as gemcitabine, irinotecan and pegylated liposomal 
doxorubicin, also show disappointing results[14,15]. 
Combination chemotherapy has been employed in the 
treatment of  advanced HCC. Although some of  the 
combination regimes have shown promising activity in 
phase Ⅱ studies, most of  them fail to demonstrate any 
survival advantage in randomized phase Ⅲ studies[16,17]. 
Especially, the combination of  cisplatin, interferon-
alpha-2b, doxorubicin and fluorouracil (PIAF) was under 
intense investigation at one time. In the phase Ⅱ study, 
Leung et al[18] showed on average 26% partial response, 
with 4 patients achieving a complete pathological 
response. Nevertheless, in the phase Ⅲ study, although 
this combination had achieved higher response rates 
than other combinations, there was no demonstrable 
survival benefit and there were considerable toxicities[19]. 
Recently, a phase Ⅱ study using a combination of  
gemcitabine and oxaliplatin demonstrated an 18% 
response rate and 76% of  patients had the disease under 
control[20]. Similarly, another phase Ⅱ study showed 
a 6% response rate and a 72% disease control rate by 
employing a 3-wk cycle of  capecitabine and oxaliplatin 
in the treatment of  advanced HCC patients[21]. However, 
as with the results from the PIAF study, these ‘promising’ 
data need to be further validated in the ongoing 
randomized phase Ⅲ trials before they can be employed 
in routine clinical practice.
HORMONAL THERAPY
Estrogen receptor, progesterone receptor and androgen 
receptor are expressed in HCC[22,23]. Thus, hormonal 
agents were used to treat advanced HCC. Among various 
hormonal agents used for the treatment of  advanced 
HCC patients, tamoxifen was frequently employed in the 
past, due to its good tolerability and oral administration. 
However, several prospective randomized controlled 
trials failed to demonstrate overall survival benefit in 
treating advanced HCC patients with tamoxifen[24-26]. 
Moreover, a recent meta-analysis conducted by Nowak 
et al[27] also showed no survival advantage.
IMMUNOTHERAPY OF HCC
Interferon is frequently employed in the treatment of  
viral hepatitis. However, its role in the treatment of  
HCC remains controversial. Studies conducted by Lai 
Chemotherapy Study No. of 
patients
Response 
   rate
Doxorubicin
   Pegylated liposomal doxorubicin Halm      16          0
   Doxorubicin Johnson      32        44
   Doxorubicin, 5-FU, mitomycin C Al-Idrissi      40        13
   Doxorubicin, bleomycin Ravry      60        16
   Doxorubicin, cisplatin Lee      37        18.9
   Doxorubicin, 5-FU, cisplatin, 
   interferon (PIAF)
Yeo      91        20.9
Cisplatin
   Cisplatin Falkson      35        17
   Cisplatin, interferon Ji      30        13.3
   Cisplatin, 5-FU, mitoxantrone Ikeda      51        27
Gemcitabine
   Gemcitabine Fuchs      30          0
   Gemcitabine Yang      28        18
   Gemcitabine, oxaliplatin Taieb      21        19
Epirubicin, etoposide
   Epirubicin Hochster      18        17
   Etoposide Melia      24        13
   Epirubicin, etoposide Bobbio- 
Pallavicini
     36        39
Others
   Mitoxantrone Lai      20          0
   Paclitaxel Chao      20          0
   Irofulven Falcon- 
Lizaraso
     29          7
   Irinotecan O'Reilly      14          7
   Nolatrexed Stuart      26          8
   T138067 Leung      21        10
   Capecitabine Patt      37        11
   5-FU, interferon Patt      28        14
Table 1  Pivotal chemotherapy trials in advanced HCC
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et al[28,29] had shown encouraging efficacy with a 30% 
response rate and overall survival benefit from using 
a high dose of  interferon (2.5 × 107-5.0 × 108 IU/m2, 
three times weekly) to treat advanced HCC patients. 
However, there were significant treatment-related 
toxicities in patients who received high-dose interferon. 
On the other hand, when a lower dosage (3 × 106 IU/m2, 
three times weekly) of  interferon was used instead, there 
was no demonstrable clinical benefit[30].
SOMATOSTATIN ANALOG TREATMENT
The somatostatin analog octreotide and the long-acting 
form lanreotide are used in treating HCC, due to the 
presence of  somatostatin receptors in HCC cells[31]. A 
randomized study, conducted by Kouroumalis et al[32], 
showed survival benefits in employing subcutaneous 
octreotide in the treatment of  advanced HCC patients.
Nevertheless, the study conducted by Becker et al[33] 
and Yuen et al[34] did not show any survival benefit in 
using lanreotide in the treatment of  advanced HCC 
patients’.
THALIDOMIDE
Thalidomide was originally introduced in the 1960s as a 
sedative[35]. It was later re-evaluated for its anti-neoplastic 
effect in the 1990s. Its mechanism of  action is poorly 
understood and complex, including anti-angiogenesis 
via the inhibition of  VEGF, tumor necrosis factor-alpha 
and modulation of  other inflammatory cytokines[36]. It 
was used in treating advanced HCC patients, mainly due 
to its anti-angiogenic property. However, single-agent 
thalidomide[37,38] and its combinations with epirubicin 
or interferon[39,40] only produced a response rate of  
3.1%-6.3% with a median survival of  2.7-6.8 mo. In 
view of  its limited activity and frequent association with 
treatment-related toxicities, it is now seldom included in 
the treatment algorithm for advanced HCC patients.
SORAFENIB FOR ADVANCED HCC
Growth factors and related receptors are often 
overexpressed and/or dysregulated in HCC. Clinical 
trials indicate that growth factor receptors and their 
related signalling pathways play important roles in HCC 
cancer etiology and progression, thus providing rational 
targets for innovative cancer therapies[41]. Among various 
growth factor pathways, the activation of  the Raf/
mitogen-activated protein kinase-extracellular signal-
regulated kinase (MAPK) pathway[42,43] plays a pivotal 
role in promoting the tumor growth. Sorafenib is an oral 
multi-kinase inhibitor that blocks tumor proliferation 
by targeting the Raf/MAPK/ERK signaling pathway; it 
also has anti-angiogenic properties attained by targeting 
the tyrosine kinase VEGR-2, VEGFR-3 and PDGF 
receptor β[44]. Recently a large randomized phase Ⅲ 
study, the SHARP trial[45], was conducted and in this 
study, 602 patients with biopsy-proven advanced HCC 
were randomized to receive either sorafenib (400 mg 
twice daily, n = 299) or a placebo (n = 303). The results 
demonstrated a significant improvement in both OS 
(median 10.7 mo versus 7.9 mo) and TTP (median 5.5 mo 
versus 2.8 mo) in the sorafenib group versus the placebo 
group. These results represented a 44% increase in OS 
(hazards ratio, 0.69; P = 0.00058) and 73% prolongation 
in the TTP (hazards ratio, 0.58; P = 0.000007). Sorafenib 
was generally well-tolerated and serious adverse events 
only occurred in 13% of  patients. This trial represents 
the first randomized systemic therapy trial that 
demonstrates the overall survival benefit of  systemic 
treatment in patients with advanced HCC thus far. 
Similar to the study design of  SHARP study, an Oriental 
sorafenib study was conducted to investigate the efficacy 
and tolerability of  using single agent sorafenib in 
treating advanced HCC patients in hepatitis-B endemic 
Asian population[46]. In this study, the median OS of  
patient on sorafenib was 6.2 mo which was significantly 
better than 4.1 mo achieved in patients on placebo 
(P = 0.0155). Again, sorafenib was well-tolerated in 
Asian patient population. However, the commonest 
toxicities encountered in Asian patient population were 
hand-foot skin reactions (10.1%) instead of  diarrhea 
(39%) in the SHARP trial.
CONCLUSION
The management of  patients with advanced HCC has 
been a disappointing issue for decades. The recent 
development of  single agent sorafenib, in the treatment 
of  advanced HCC patients, indeed represents an 
important advance in this challenging disease. Although 
these two pivotal studies have demonstrated good activity 
and tolerability in treating advanced HCC patients with 
sorafenib, there are still many unresolved issues regarding 
the optimal use of  sorafenib. In particular, most patients 
enrolled in these two pivotal trials had Child-Pugh A 
cirrhosis with favorable clinical parameters. Therefore, 
the benefits and safety profile of  sorafenib in unselected 
advanced HCC patients, especially those with Child-
Pugh B/C patients or other poor prognostic factors, 
are still unknown. Moreover, there are currently no 
reliable clinical parameters or biomarkers which may 
predict the response to sorafenib. In view of  the high 
cost of  sorafenib and potential toxicities associated with 
sorafenib, reliable biomarkers that can potentially guide 
the use of  sorafenib in the treatment of  advanced HCC 
patients is desperately needed.
Moreover, in the era of  targeted therapy, proper 
patient selection, treatment assessment and endpoints are 
vital to the success of  the clinical trials. This is especially 
true in HCC, where radiological assessment is difficult, 
because of  poor delineation of  the tumor in the liver. 
Recently, the HCC expert panel meeting recommended 
adopting a modification of  RECIST criteria to assess 
tumor response[47]. Also, the time to progression was 
recommended by the panel as the primary endpoint in 
phase two trials testing targeted therapy in HCC.
The modest improvement, as demonstrated in these 
two pivotal trials; is still not optimal, as most patients 
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still have relatively short survival times when compared 
to patients with other solid tumors, such as colorectal 
cancer. Therefore, there is a need for researchers to 
unravel more of  the underlying hepato-carcinogenesis 
mechanism and key molecular targets for therapeutic 
intervention. Moreover, another future focus will be 
on how to best combine the other targeting agents 
or chemotherapeutic agents in order to incrementally 
improve the survival of  advanced HCC patients.
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